Grammatical mood

Study finds link between air pollution and increased depression symptoms in people with bipolar disorder

Retrieved on: 
Tuesday, December 6, 2022

BOSTON, Dec. 6, 2022 /PRNewswire/ -- Researchers at University College London (UCL) published the results of the first study to find that short-term air pollution exposure is associated with acutely increased depression symptoms in people with bipolar disorder.

Key Points: 
  • BOSTON, Dec. 6, 2022 /PRNewswire/ -- Researchers at University College London (UCL) published the results of the first study to find that short-term air pollution exposure is associated with acutely increased depression symptoms in people with bipolar disorder.
  • The study, "Real-time air pollution and bipolar disorder symptoms: a remote monitored cross-sectional study," is the first to compare daily air quality index (AQI) data with patients' scores on clinical-grade surveys of depression and mania.
  • The study found that as air quality worsened, symptoms of depression increased.
  • "This study suggests that air pollution may represent an important modifiable risk factor for symptom severity in a range of mental health problems including bipolar disorder."

New Securus Originals' Podcast Inspires Incarcerated Individuals to Focus on Building a Second Chance Beginning Day One of Incarceration

Retrieved on: 
Thursday, December 1, 2022

DALLAS, Dec. 1, 2022 /PRNewswire/ -- Securus Technologies, an Aventiv company driving efforts to better serve the incarcerated through rehabilitative justice, today announced the availability of a new 12-episode podcast series on Securus Originals, titled "Day One with Andre Norman." Created and hosted by Andre Norman, who turned his life around from prison gang leader to international speaker and Harvard fellow, Norman's guests illustrate how the first days, weeks, and months of incarceration can be instrumental to a successful reentry. Each episode shares stories of formerly incarcerated individuals and how they made the best of their time behind the walls to create a real opportunity for a changed life following incarceration. The podcast series is available for free to incarcerated individuals who have access to the Securus tablets and free to the public on the Securus YouTube channel, Spotify, Amazon Music, and the Apple podcast store.

Key Points: 
  • The podcast series is available for free to incarcerated individuals who have access to the Securus tablets and free to the public on the Securus YouTube channel, Spotify, Amazon Music, and the Apple podcast store.
  • "Day Onewith Andre Norman" stands out not only because it was created by a formerly incarcerated individual, but also because the podcast features guests who were previously incarcerated speaking to a currently incarcerated population.
  • Each episode offers guidance for the incarcerated to change their thinking and set themselves on a positive path beginning their first day in a facility.
  • This is an extension of Securus' broader commitment to support the incarcerated as they build skills and resilience for a better future.

Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, December 1, 2022

Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.

Key Points: 
  • Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.
  • Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2019.
  • Its also the first TAAR1 agonist to enter into a Phase 2/3 clinical study as an adjunctive therapy for MDD.
  • Major depressive disorder is a chronic debilitating disease characterized by symptoms that last at least two weeks causing significant functional impairment.

Memory Fitness Among Fastest-Growing Medicare Advantage Benefits

Retrieved on: 
Thursday, December 1, 2022

A recent analysis of 2022 federal data reveals that a new type of fitness benefit memory fitness is among the fastest growing preventive health benefits .

Key Points: 
  • A recent analysis of 2022 federal data reveals that a new type of fitness benefit memory fitness is among the fastest growing preventive health benefits .
  • According to Posit Science , their BrainHQ online brain fitness program is the choice of most Medicare Advantage organizations across the United States offering a memory fitness supplemental benefit.
  • It was first permitted under a regulatory change for 2019, and, starting in 2021, the government asked plans to differentiate among physical fitness (such as gym memberships), wearable fitness trackers, and memory fitness programs.
  • Our own market research indicates that mind/body fitness really resonates with older adults new to Medicare, Dr. Mahncke added.

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

Retrieved on: 
Wednesday, November 30, 2022

Phase 1 clinical trial under Vistagens newly filed Investigational New Drug (IND) application for clinical development of PH10 in the U.S. as a standalone treatment for major depressive disorder (MDD).

Key Points: 
  • Phase 1 clinical trial under Vistagens newly filed Investigational New Drug (IND) application for clinical development of PH10 in the U.S. as a standalone treatment for major depressive disorder (MDD).
  • People living with major depressive disorder urgently need new and differentiated therapies we are committed to addressing that need.
  • The FDAs clearance to advance our clinical program for PH10 in the U.S. is another important milestone for our company, stated Shawn Singh, Chief Executive Officer of Vistagen.
  • The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law.

Research shows nearly three-quarters of social housing residents would not be able to cope with an unexpected expense

Retrieved on: 
Wednesday, November 30, 2022

LONDON, Nov. 30, 2022 /PRNewswire/ -- The Resident Voice Index™ (RVI), a project that gathers the views of social housing residents from across the UK, released its latest report, Cost of Living: Crunch Time, which indicated most respondents are experiencing a lower quality of life. Based on a survey of 5,700 respondents, the report reveals that almost three-quarters (73%) said they would not be able to cope with an unexpected expense, such as a higher-than-expected household bill.

Key Points: 
  • More than ever, intervention is required to avoid catastrophic consequences for UK social housing residents it really is crunch time."
  • The project's goal is to shine a light on the resident perspective and ensure that their voice is heard to help improve the experiences of social housing residents.
  • The Resident Voice Index project is a long-term project that asks questions of a broad spectrum of social housing residents.
  • Worldwide, MRI Software serves more than 3,000 organisations in social, affordable, public and community housing.

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, November 29, 2022

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.

Key Points: 
  • Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.
  • ABX-002 is a potent and selective, brain-boosting thyroid receptor beta (TR) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.
  • We look forward to advancing ABX-002 in the clinic as we further our understanding of its potential impact for patients.
  • Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.

neurocare group AG Announces Publication Confirming the Importance of Sleep for Effectiveness of Combined rTMS and CBT for OCD

Retrieved on: 
Monday, November 21, 2022

The study confirms the importance of sleep for the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in combination with cognitive behavioral therapy (CBT) as treatment for obsessive-compulsive disorder (OCD).

Key Points: 
  • The study confirms the importance of sleep for the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in combination with cognitive behavioral therapy (CBT) as treatment for obsessive-compulsive disorder (OCD).
  • In this study, the authors investigated if sleep problems may be associated with the response to rTMS in patients with treatment-resistant OCD.
  • Study results show that combining rTMS with CBT may be more effective than rTMS alone as 60% of patients with OCD benefit from the combination therapy.
  • In this study, 61 patients with treatment-resistant OCD received a combined treatment of rTMS and cognitive behavioral therapy at three neurocare Group clinicsin Nijmegen, the Haag, and Eindhoven, the Netherlands.

Frankly’s Online Wellness Coaching Now Available Nationwide

Retrieved on: 
Tuesday, November 15, 2022

Demand for mental wellness services is skyrocketing and many people are finding themselves struggling to find available therapists, counselors, and psychiatrists.

Key Points: 
  • Demand for mental wellness services is skyrocketing and many people are finding themselves struggling to find available therapists, counselors, and psychiatrists.
  • Frankly believes wellness coaching provides a path to therapeutic support that can bridge the gap in availability and accessibility of traditional therapy.
  • We believe mental wellness coaching is an affordable addition for anyone on a mental wellness journey.
  • Frankly is a holistic mental wellness platform that provides members with the perfect mix of mental wellness coaching and mental health treatment.

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022

Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.

Key Points: 
  • Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.
  • General and administrative expenses for the third quarter ended September 30, 2022 were $0.9 million, compared to $1.1 million for the third quarter ended September 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on November 14, 2022, at 8:30 a.m.
  • ET to discuss the Companys financial results and provide a corporate update.